Eva Schaeffer

TL;DR: The existence of brain-first and body-first subtypes of Parkinson's disease is supported by quantifying neuronal dysfunction in structures corresponding to Braak stages I, II and III involvement in three distinct patient groups using multimodal imaging.

TL;DR: In this article, the authors classified clinical and prodromal PD into subtypes with different clinical manifestations, pathomechanisms and patterns of spatial and temporal progression in the CNS and PNS.

TL;DR: In this article, the International Parkinson Disease and Movement Disorders society (MDS) diagnostic criteria against a gold-standard expert clinical diagnosis and to compare concordance/accuracy of the MDS criteria to 1988 United Kingdom brain bank criteria were calculated.

TL;DR: In this article, the authors proposed a new approach for the assessment of the individual probability of prodromal PD in two independent prospective studies, namely, the Tubingen Evaluation of Risk Factors for Early Detection of Neurodegeneration cohort (TREND) and the population-based Prospective Evaluation of risk factors for Idiopathic Parkinson's Syndrome cohort (PRIPS Tubingen subsample; n = 10; PRIPS = 7).

TL;DR: Targets of continuous dopaminergic stimulation seem the most promising to prevent or ameliorate LID, and the success of future therapeutic strategies once moderate to severe LID occur will depend on the translation from preclinical experimental models into clinical practice in a bidirectional process.